[A chance we take...].
Paley-Vincent
C
C
D016907:Adverse Drug Reaction Reporting Systems; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D005062:European Union; D005602:France; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007258:Informed Consent / Q000331:legislation & jurisprudence*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000209:etiology*; D010817:Physician-Patient Relations; D017410:Practice Guidelines as Topic; D011565:Psoriasis / Q000188:drug therapy*; D018570:Risk Assessment; D056737:Safety-Based Drug Withdrawals; D014342:Truth Disclosure
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C472181:efalizumab